Literature DB >> 1966702

Prevalence of antibody to hepatitis C virus (anti-HCV) in chronic liver diseases (CLD) in southern Italy.

L Amitrano1, A Ascione, C Canestrini, S D'Agostino, L Iaccarino, C Vacca, T Gigliotti.   

Abstract

Two hundred and sixty-three patients consecutively admitted to our Unit for CLD were investigated for the antibody to Hepatitis C Virus (anti-HCV) in the serum using the recently developed enzyme immunoassay. The overall prevalence of anti-HCV was 45%; in patients with cryptogenic CLD it was significantly higher (69%) than in patients with markers of viral hepatitis (15%). Anti-HCV was found in 62% of the patients with hepatocellular carcinoma; this finding favours a potential role of HCV in determining the neoplastic transformation of the cirrhotic liver. In alcoholic liver disease the prevalence of anti-HCV was 52%; this finding poses the interesting question of aethiology of liver damage in these patients. The presence of anti-HCV was significantly associated with older age, irrespective of aethiology and stage of liver disease. The importance of the detection of this antibody for the aethiological diagnosis of chronic liver damage remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1966702

Source DB:  PubMed          Journal:  Ital J Gastroenterol        ISSN: 0392-0623


  2 in total

1.  The frequency of complications and the etiology of disease in patients with liver cirrhosis in erzurum.

Authors:  Omer Topdagi; Nihat Okcu; Nurhan Bilen
Journal:  Eurasian J Med       Date:  2014-06

2.  Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.

Authors:  Antonio Ascione; Massimo De Luca; Mario Melazzini; Simona Montilla; Maria Paola Trotta; Salvatore Petta; Massimo Puoti; Vincenzo Sangiovanni; Vincenzo Messina; Savino Bruno; Antonio Izzi; Erica Villa; Alessio Aghemo; Anna Linda Zignego; Alessandra Orlandini; Luca Fontanella; Antonio Gasbarrini; Marco Marzioni; Edoardo G Giannini; Antonio Craxì
Journal:  Infection       Date:  2018-05-28       Impact factor: 7.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.